We work with today's informed and empowered patients to ensure our solutions are designed for and reach the people who need them.
Patient Engagement is everyone's responsibility at Janssen, exemplified by support from the highest levels of our organization. Learn more about our integrated, cross-functional Patient Engagement Leadership Team.
Katherine Capperella is Global Head, Patient Engagement Leader at Janssen. In this role, Katherine leads a cross-functional team responsible for developing and driving patient engagement strategy and measuring progress over time. She and her team are focused on leading Janssen to incorporate direct patient voice early and throughout the entire product lifecycle, beginning with disease area strategies and including target product profiles, formulations, clinical trials and post-marketing activities.
Katherine has more than 20 years of experience at Johnson & Johnson in roles of increasing responsibility. Previously, Katherine served as global commercial vice president for Janssen’s Active Pharmaceutical Ingredients (API) business developing pharmaceutical ingredients for pain. Prior to that, Katherine led a cross-functional team responsible for commercial assessments of licensing and acquisition opportunities for Janssen neuroscience. Katherine began her career in women’s health and has demonstrated success in launch, turnaround and mature businesses in a variety of disease areas.
Katherine holds a Bachelor of Science in Business/Marketing from the Kelley School of Business.
Carrie Corboy is the Senior Director, Standards & Execution Excellence at Janssen Pharmaceutical Companies of Johnson & Johnson. She currently supports the Janssen global commercial organization including capturing performance metrics in patient engagement and establishing a framework for complying with company policies and global requirements while encouraging engagement with patients. Carrie’s career spans over 20 years with experience in the biopharmaceutical industry in the areas of pharmacovigilance, regulatory affairs, regulatory policy, compliance and clinical development.
Carrie started her career at Johnson & Johnson Pharmaceutical Research & Development in 2001, serving in roles as Director of Standards & Execution Excellence and Senior Scientist of Aggregate Reporting. A licensed pharmacist, prior to joining Johnson & Johnson, she worked in pharmacist and directorial roles in organizations including Advanced Biologics and Bristol Myers Squibb. She is an active member of the New Jersey Pharmacists Association (NJPhA).
Carrie holds her Bachelor of Science degree in Pharmacy from Rutgers University-New Brunswick, New Jersey, and her Doctor of Pharmacy degree from University of the Sciences in Philadelphia, Pennsylvania.
Daniel De Schryver is Patient Engagement & Advocacy Lead for Europe, Middle East and Africa (EMEA).
In this function, Daniel is part of a global multi-functional leadership team that helps the company to engage with patients in a systematic way and helps to build partnerships in developing solutions that better meet the existing needs. He also leads a team in the EMEA region who play a crucial role in working towards a more collaborative approach in innovation.
Daniel joined Johnson & Johnson in 2001 as Director, Corporate Communications. In that function, he initially worked in the field of oncology. In 2006 he joined the Janssen teams working in Infectious Diseases where he helped to maintain and enhance the company’s relationships with the HIV Patient Community. Later, he built the external relationships in the field of Hepatitis C, before becoming the Global Therapeutic Area Communications Leader Infectious Diseases and Vaccines. In this function he developed world wide strategic communications and public affairs programs about infectious diseases and global public health.
Before joining Johnson & Johnson, he worked at Burson-Marsteller as corporate communications consultant. Daniel started his communications career in the car industry for several years, he joined the non-profit sector and became country manager for Médecins Sans Frontières in Bosnia, Croatia and Angola. Back in Europe, he headed the Communications department for the organization.
Daniel has a Master in Romance Philology (Literature) and he started his career as a teacher. His personal interests are contemporary art and architecture, politics and meeting people.
Joaquin Garcia-Lopez is Director, Market Research Excellence for the Global Commercial Strategy Organization (GCSO) at Janssen. In this role, Joaquin is responsible for driving functional excellence in market research across the global team, bringing together analytics professionals in GCSO and regional commercial roles to accelerate best practice sharing regarding market research methodologies and implementation. He partners with market researchers within GCSO Therapy Area teams to drive cutting-edge research to support development decisions for compounds in Janssen’s R&D pipeline. His focus includes providing guidance on reliable methods for unearthing rich patient emotional and rational insights to fuel asset strategies throughout the disease continuum and product life cycles.
Joaquin joined Janssen in 2015 as Associate Director of Global Market Research for the Neurodegeneration Disease Area Stronghold within GCSO. In this role, Joaquin was responsible for the generation of actionable customer analytics and insights to help the Neurodegeneration team identify ways to build and maximize the value of its global pipeline assets. He was the market research lead on a wide range of programs related to the future management of preclinical Alzheimer’s disease and served as commercial lead for the alpha-2C inhibitor asset and atabecestat’s EARLY trial communications program.
In his previous role, Joaquin was Vice President of healthcare research at ORC International, a market research and business intelligence firm. In this role, he worked with a broad portfolio of pharmaceutical clients and led consultative market analytics meeting a range of business needs such as new product development, lifecycle management strategies and various drug launches. Joaquin started his pharmaceutical career as a bench biomedical engineer at Forticell Bioscience’s process development group, where he worked on the development and launch of novel cell therapies and advanced biomaterials.
Joaquin graduated from Columbia University with both an Master of Science in Technology Management and a Bachelor of Science in Biomedical Engineering and holds a B.A. in Mathematics from Fordham University.
Tammy is the Global Lead of Janssen Clinical Innovation, with more than 20 years of experience in strategic and operational delivery across clinical development, regulatory affairs, and healthcare innovation.
Based in New Jersey, she currently leads the creation and scaling of new operational approaches and technologies into clinical research with the goals of expediting drug development, reducing overall costs, and improving patient and site experiences.
Through the design and conduct of novel trial models and demonstration projects, Tammy is responsible for the overall performance and portfolio optimization of JCI, generating data and knowledge about the feasibility, impact, and value of new capabilities.
Tammy previously served as Head of Central Clinical Planning & Solutions at Bristol Myers Squibb, where she led a global team that expedited clinical trials through application of external insights, analytics and digital technology.
Beverly Harrison is responsible for leading the Patient Support Group reporting directly to the Chief Medical Officer at Janssen R&D, the research arm of Johnson & Johnson, focusing on developing strategies to understand and support the needs of patients by working with internal and external stakeholders, including a special focus on engaging patient advocacy organizations.
She is a research, development, and nonprofit patient advocacy professional with more than 20 years of leadership experience integrating team efforts across functions with increasingly high levels of responsibility for impacting the policies and performance of pharmaceutical, CRO and nonprofit organizations.
Beverly holds a Bachelor of Science in Political Science degree from William & Mary, Williamsburg, Virgina.
Rochelle Kleinberg is the Director for Healthcare Solutions at Johnson & Johnson Design. She brings significant design and strategic experience to the development of holistic, patient-centered solutions that empower people with health conditions to better manage therapy and enable improved health outcomes.
Rochelle joined Johnson & Johnson in 2008, first as Design Strategy Director, then as Industrial Design Director before taking on her current role focusing on J&J Design’s collaboration with Janssen. A champion for human-centered design and patient engagement, she works with numerous internal and external stakeholders to develop and realize products and experiences that address the unmet needs of patients and all those involved in their care.
Prior to joining Johnson & Johnson, Rochelle was the Creative Director for North America for Dyson Inc., Executive Director of Global Package Design for Clinique Laboratories LLC, part of the Estée Lauder Companies, and Senior Designer at TKO Design in London working on a diverse range of projects for clients such as Sony, Honda, Sanyo, Hasbro and Procter & Gamble.
She holds a Bachelor of Architecture degree from Carnegie Mellon University and a Master of Arts in Industrial Design from Central Saint Martins in London.
Pauline McNulty is Vice President, Patient Reported Outcomes, Global Market Access in the Global Commercial Strategy Organization at Janssen. In this role, she is responsible for ensuring the patient’s perspective is appropriately incorporated into global drug development programs through measurement of Patient Reported Outcomes (PROs). In addition, she leads several internal programs related to talent development in the global market access community at Janssen.
Pauline joined Johnson & Johnson in 1994 as a Director in the Health Economics department. Since that time, she has held positions of broad and increasing responsibility, including Vice President Health Economics, when she was responsible for health economics for all products in development, and Vice President Health Economics & Pricing when she was responsible for market access for products in the Internal Medicine portfolio.
Previously, Pauline worked at Schering-Plough, where she was Director Pharmacoeconomics for Respiratory and Cardiovascular products in development as well as those already on the market. Prior to joining the pharmaceutical industry, she worked for a healthcare research and consulting company, SysteMetrics, in Santa Barbara, California.
Pauline has been involved in several external initiatives and forums that relate to patient representation and outcomes. In 2009-2010, Pauline served as a member of the Steering Committee for the National Quality Forum’s (NQF) National Voluntary Consensus Standards for Patient Outcomes. Currently, she is a member of the PhRMA Patient Focused Drug Development Work Group and the National Health Council’s Patient Engagement Work Group. Within Janssen, she is a member of the Global Patient Engagement Team, whose mission is to partner with patients and caregivers from an early stage of drug development to maintain an ongoing dialogue to develop solutions that better meet their needs
Pauline received her Ph.D. in experimental psychology from the University of California, Santa Barbara. She has an Master of Science in Experimental Psychology and a Bachelor of Science in Science from University College Dublin. She has published several articles related to health economics and patient reported outcomes and the patient’s perspective in drug treatment. From 2009- 2011, Pauline participated in Johnson & Johnson’s Health Policy Excellence Program through the Jefferson School of Population Health.
Michael Mitchell is the Communication Leader, Global Commercial Strategy Organization (GCSO) and R&D Executive Support within the Janssen R&D Communication team.
Michael is responsible for building and leading the strategic planning, development and implementation of integrated external and internal communication for GCSO, Janssen’s Patient Engagement strategy, as well as providing R&D executive communication support. He has also been instrumental in the launch of Janssen One, the long-term global strategy for the company.
Michael joined Johnson & Johnson in October of 2016. Previously, he was with The Medicines Company for 14 years in a variety of roles of increasing responsibility, including as Value Development Lead for Kengreal (cangrelor), where he was responsible for economics and reimbursement, and market access to prepare for launch of Kengreal in the United States. Prior to that position, Michael was Head of Global Communications where he led investor, employee, and product communication. Michael also held the position of Executive Director of Corporate Affairs and Critical Care Business Manager for Northern New Jersey.
Prior to joining The Medicines Company, Michael advised biotechnology clients at Feinstein Kean Healthcare and started his career at Edelman Healthcare.
He currently serves on the Board of the First Tee of Greater Trenton. Michael also served on the Executive Committee for the American Heart Association (AHA) Morris County Heart Walk, 5K run from 2010 through 2014.
Michael earned his Master’s in Business Administration from Rutgers, The State University of New Jersey and his Bachelor of Science in Health Policy and Management from Providence College.
Lisa Shea is the Scientific Patient Engagement Leader for Janssen Scientific Affairs. Lisa is responsible for bringing the patient perspective in-house and leveraging it to drive high priority patient-centered activities from the earliest stages of strategy development to final stages of project execution. She will lead the strategic development and execution of patient-centered research and engagement from within Janssen Scientific and Medical Affairs and with partners across North America Pharmaceuticals and Janssen.
Previously, Lisa spent four years leading the strategy and operations for the Integrated Evidence Generation Planning (IEGP) and Integrated Evidence Team Leader (IETL) community, working seamlessly with internal stakeholders to operationalize IEGPs across all Integrated Evidence Teams (IETs) while driving connectivity across the scientific community.
Prior to joining Johnson & Johnson, Lisa worked in Public Policy at GlaxoSmithKline. She was a Health Policy Liaison in U.S. Medical Affairs where she led external engagement planning with evidence-generating agencies such as the Patient-Centered Outcomes Research Institute (PCORI). She also helped embed the patient voice into various phases of the study life cycle while strengthening internal capabilities across the Commercial business and R&D, including the Patient Advocacy teams.
Lisa holds a master’s degree in public health from Drexel University in Philadelphia, Pennsylvania, and has more than 15 years of experience in the health care industry. She is a Registered Dietitian, working in both the acute care and long-term care hospital settings, and a Project Lead in the design of a novel community-based participatory research project to improve nutrition and exercise outcomes across three school districts in suburban Philadelphia.
